Key Highlights
- 0.13 is the loss per share in USD implied by the consensus EPS estimate of -0.13 for TuHURA Biosciences, Inc. (NASDAQ:HURA), which reports third quarter 2026 results before the market opens on November 13, 2026.
- 8.7 million USD is the combined second quarter 2026 Research and Development expense of USD 6.6 million and general and administrative expense of USD 2.1 million, compared with USD 4.9 million and USD 1.9 million a year earlier.
- 1.0 million USD was the cash balance at June 30, 2026, while a USD 50 million Credit Facility and Royalty transaction from the largest Shareholder is intended to extend the cash runway into 2028.
- 96.86 million USD is the market Capitalization per the screener snapshot, below USD 100 million, against roughly 63.7 million shares outstanding at June 30, 2026, which raises small-cap Liquidity and dilution questions.
What Investors Expect From TuHURA Biosciences, Inc. (NASDAQ:HURA) on November 13, 2026
Per the screener snapshot, TuHURA Biosciences, Inc. reports third quarter 2026 results on November 13, 2026, before the market opens, with a consensus EPS estimate of -0.13 and a market capitalization of USD 96.86 million. The second quarter combined operating expenses of USD 8.7 million (calculated) spread over about 63.7 million shares imply roughly USD 0.14 per share (calculated), close to the estimate. A net loss and per-share figure for the second quarter, and a prior-year third quarter comparison, were not found in published coverage.
The Rationale: Last Reported Quarter and Management Outlook for TuHURA Biosciences, Inc. (NASDAQ:HURA)
In the second quarter of 2026, research and development rose USD 1.7 million to USD 6.6 million on clinical activity, and general and administrative expense rose USD 0.3 million to USD 2.1 million on Stock Compensation and public company costs. Six-month cash used in operations was USD 13.0 million versus USD 10.9 million, offset by USD 10.6 million of financing inflows versus USD 8.1 million. Management expects Orphan Drug designation for IFx-2.0 in Merkel cell carcinoma in the second half of 2026, preliminary investigator-study data in the first half of 2027 and Phase 3 enrollment completion in the second half of 2027. TBS-2025 is expected to start a Phase 1b/2 trial in AML in the second half of 2026.
Valuation, Liquidity and Risks for TuHURA Biosciences, Inc. (NASDAQ:HURA)
Cash of USD 1.0 million against six-month operating cash use of USD 13.0 million means near-term funding depends on facility draws. The facility bears 12% interest paid monthly, with principal due April 21, 2031, and only USD 5.7 million had been received, including USD 2.15 million after June 30, 2026. At-the-market sales raised USD 0.3 million in April and USD 0.1 million in July. At a Market Value below USD 100 million, small-cap and nano-cap stocks can be volatile and illiquid, and dilution, related-party financing and trial setbacks are key risks.
Where Things Stand
Where things stand: TuHURA Biosciences, Inc. (NASDAQ:HURA) reports with a consensus EPS estimate of -0.13, a snapshot market capitalization of USD 96.86 million and USD 1.0 million of cash at June 30, 2026. The company describes a USD 50 million facility as extending runway into 2028, yet only USD 5.7 million had been received by mid-August. Clinical milestones for IFx-2.0 and TBS-2025 cluster in the second half of 2026 and the first half of 2027, so financing and timing updates are likely to dominate the call. The call time has not been confirmed in the snapshot. This is information only and not Investment advice.


_11_20_2026_14_55_23_118425.jpg)



Please wait processing your request...